Next-Generation CT Brain AI Solution Improves Clinical Accuracy and Efficiency

An AI-enabled software-as-a-medical device (SaMD) decision-support solution for non-contrast CT brain studies can identify 130 imaging findings, including a wide range of conditions that require time sensitive interventions, making it the most clinically comprehensive decision support AI solution available on the market.

The Enterprise CTB (Annalise CTB) from Annalise.ai (Sydney, Australia) is designed to be an assistive clinical tool, empowering radiologists with a ‘second pair of eyes’ to help them improve diagnostic accuracy and health outcomes for patients. The support from Annalise CTB could be particularly impactful to overstretched radiology residents reporting out-of-hours at teaching hospitals and in areas experiencing challenging radiologist capacity constraints. In addition to assisting with the detection of imaging findings, Annalise CTB is expected to streamline patient care workflows - and analyzing non-contrast head CT examinations as they are acquired, the solution can provide a notification signal for urgent cases, helping radiologists to triage high-priority cases in need of rapid action.

Annalise Enterprise CTB is the first commercially available medical imaging AI solution to detect over 100 findings on non-contrast CT brain scans and has been trained on one of the world’s largest label datasets of non-contrast CT brain studies, hand-labeled by 143 radiologists, generating over 240,000,000 CTB labels. Designed for clinicians, with features such as a confidence bar for each finding and a user interface that provides seamless integration into a radiologist’s workflow, Annalise Enterprise CTB automatically highlights the suspected location of findings on multiplanar reformatted images with pathology-appropriate window and level settings. Annalise Enterprise CTB demonstrated improvements in reporting accuracy and changes to patient management in a recent six-week pilot study with 11 radiologists using the solution as an assistive tool. Annalise Enterprise CTB is now clinically available in Australia, New Zealand and the UK where it is in use by many radiologists at a large number of sites. The new Annalise CTB module is expected to help continue to work towards its mission to help one million patients every day.

"Annalise Enterprise CTB represents an evolutionary leap forward in AI technology for neuroimaging," said Dr. Rick Abramson, Chief Medical Officer of annalise.ai. "Whereas most other AI products for head CT can recognize only a small handful of conditions, Annalise CTB assists the radiologist with 130 imaging findings - which means more support for the radiologist and a bigger impact on patient care. In our controlled product launch, we have already seen countless examples of critical pathology that could have been missed but were successfully identified by Annalise CTB."

Related Links:
Annalise.ai